NBIX vs. OPRA
NBIX (Neurocrine Biosciences, Inc.) and OPRA (Opera Limited) are both stocks. NBIX operates in Drug Manufacturers - Specialty & Generic (Healthcare), while OPRA operates in Internet Content & Information (Communication Services). Over the past 5 years, NBIX returned 12.33%/yr vs 19.43%/yr for OPRA. At a 0.15 correlation, their price movements are largely independent.
Performance
NBIX vs. OPRA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBIX achieves a 24.87% return, which is significantly lower than OPRA's 42.17% return.
NBIX
- 1D
- -1.91%
- 1M
- 8.85%
- 6M
- 30.43%
- YTD
- 24.87%
- 1Y
- 32.71%
- 3Y*
- 21.73%
- 5Y*
- 12.33%
- 10Y*
- 13.85%
OPRA
- 1D
- -0.52%
- 1M
- 10.19%
- 6M
- 45.48%
- YTD
- 42.17%
- 1Y
- 9.17%
- 3Y*
- -4.32%
- 5Y*
- 19.43%
- 10Y*
- —
NBIX vs. OPRA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 24.87% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -33.93% |
OPRA Opera Limited | 42.17% | -22.08% | 52.02% | 140.60% | -10.91% | -22.67% | -1.30% | 66.37% | -61.23% |
Correlation
The correlation between NBIX and OPRA is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.14 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.16 |
Correlation (All Time) Calculated using the full available price history since Jul 27, 2018 | 0.15 |
Fundamentals
NBIX:
$17.81B
OPRA:
$1.72B
NBIX:
$6.50
OPRA:
$1.26
NBIX:
27.23
OPRA:
15.23
NBIX:
0.54
OPRA:
0.06
NBIX:
5.87
OPRA:
2.70
NBIX:
5.37
OPRA:
1.77
NBIX:
$3.10B
OPRA:
$647.66M
NBIX:
$3.05B
OPRA:
$378.92M
NBIX:
$881.20M
OPRA:
$154.47M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. OPRA — Risk / Return Rank
NBIX
OPRA
NBIX vs. OPRA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Opera Limited (OPRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBIX | OPRA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.95 | ||
| Sortino ratioReturn per unit of downside risk | +1.01 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.05 | +0.15 |
| Calmar ratioReturn relative to maximum drawdown | 1.50 | 0.05 | +1.45 |
| Martin ratioReturn relative to average drawdown | 3.29 | 0.09 | +3.20 |
Loading charts...
Drawdowns
NBIX vs. OPRA - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than OPRA's maximum drawdown of -72.85%. Use the drawdown chart below to compare losses from any high point for NBIX and OPRA.
Loading charts...
Drawdown Indicators
| NBIX | OPRA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -72.85% | -24.36% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -41.28% | +20.38% |
Max Drawdown (3Y)Largest decline over 3 years | -42.89% | -61.68% | +18.79% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -61.97% | +19.08% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | — | — |
Current DrawdownCurrent decline from peak | -1.91% | -19.94% | +18.03% |
Average DrawdownAverage peak-to-trough decline | -43.74% | -40.90% | -2.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.52% | 23.37% | -13.85% |
Volatility
NBIX vs. OPRA - Volatility Comparison
The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 8.08%, while Opera Limited (OPRA) has a volatility of 10.70%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than OPRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBIX | OPRA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.08% | 10.70% | -2.62% |
Volatility (6M)Calculated over the trailing 6-month period | 23.42% | 39.68% | -16.26% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.73% | 52.04% | -20.31% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.83% | 60.50% | -27.67% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.03% | 64.11% | -25.08% |
Dividends
NBIX vs. OPRA - Dividend Comparison
NBIX has not paid dividends to shareholders, while OPRA's dividend yield for the trailing twelve months is around 4.17%.
| Position | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% |
OPRA Opera Limited | 4.17% | 5.65% | 4.22% | 8.92% |
Financials
NBIX vs. OPRA - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Opera Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. OPRA - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
OPRA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Opera Limited reported a gross profit of 111.02M and revenue of 175.77M. Therefore, the gross margin over that period was 63.2%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
OPRA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Opera Limited reported an operating income of 30.43M and revenue of 175.77M, resulting in an operating margin of 17.3%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
OPRA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Opera Limited reported a net income of 24.79M and revenue of 175.77M, resulting in a net margin of 14.1%.
Frequently Asked Questions
NBIX and OPRA have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
OPRA has higher volatility (10.70%) compared to NBIX (8.08%). In terms of maximum drawdown, NBIX dropped -97.21% vs OPRA's -72.85%.
NBIX currently has the higher Sharpe Ratio (0.99 vs 0.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NBIX and OPRA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer